U.S., June 12 -- ClinicalTrials.gov registry received information related to the study (NCT07642843) titled 'CM336 for Active Sjogren's Syndrome Study' on June 08.
Brief Summary: The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and efficacy of CM336 in adult participants with active primary Sjogren's Syndrome.
Study Start Date: June, 2026
Study Type: INTERVENTIONAL
Condition:
Primary Sjogren's Syndrome (pSS)
Intervention:
BIOLOGICAL: CM336
Participants will receive CM336 via subcutaneous injection in ascending dose cohorts
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Keymed Biosciences Co.Ltd
Published by HT Digital Content Services with permission from Health Daily Digest....